Randomized Phase II or first line phase III studies
•
FOLFIRINOX
PEGPH20
•
Gemcitabine + Nab-paclitaxel
PEGPH20
•
Ibrutinib
•
MM-141
•
BBI-608
•
US: 54 Phase 1-3 trials for metastatic disease, only 2 incorpórate
FOLFIRINOX.
M. Tempero, presented in WGI 2016